BrainStorm Announces the Publication of Preclinical Data Highlighting the Potential of a NurOwn® Derived Exosome-Based Treatment for COVID-19 ARDS
Stock Information for Brainstorm Cell Therapeutics Inc.
Loading
Please wait while we load your information from QuoteMedia.